share_log

UBS Initiates Coverage On Telix Pharmaceuticals With Buy Rating, Announces Price Target of $21

Benzinga ·  Nov 15 20:26  · Ratings

UBS analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:TLX) with a Buy rating and announces Price Target of $21.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment